1. Home
  2. AKRO
  3. AKRO News

Latest Akero Therapeutics Inc. (AKRO) News on January 19, 2025

Akero Therapeutics Completes Enrollment of the Double-Blind Portion of the Phase 3 SYNCHRONY Real-World Study Evaluating Efruxifermin (EFX) in Patients with Non-Invasively Diagnosed MASH or MASLD
AKRO

GlobeNewswire

6 days ago

Akero Therapeutics Completes Enrollment of the Double-Blind Portion of the Phase 3 SYNCHRONY Real-World Study Evaluating Efruxifermin (EFX) in Patients with Non-Invasively Diagnosed MASH or MASLD

Akero Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
AKRO

GlobeNewswire

12 days ago

Akero Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

AKRO

MT Newswires

12 days ago

Akero Therapeutics Insider Sold Shares Worth $280,330, According to a Recent SEC Filing

Why Is Akero Therapeutics, Inc. (AKRO) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?
AKRO

Insider Monkey

a month ago

Why Is Akero Therapeutics, Inc. (AKRO) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?

Akero Therapeutics to Present at the 7th Annual Evercore ISI HealthCONx Conference
AKRO

GlobeNewswire

2 months ago

Akero Therapeutics to Present at the 7th Annual Evercore ISI HealthCONx Conference

AKRO

MT Newswires

2 months ago

Citigroup Initiates Akero Therapeutics at Buy With $65 Price Target

Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024
AKRO

GlobeNewswire

2 months ago

Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024

Akero Therapeutics to Present at the Jefferies London Healthcare Conference
AKRO

GlobeNewswire

2 months ago

Akero Therapeutics to Present at the Jefferies London Healthcare Conference

Akero Therapeutics Advances in MASH Treatment Trials
AKRO

TipRanks

2 months ago

Akero Therapeutics Advances in MASH Treatment Trials

AKRO

MT Newswires

2 months ago

Akero Therapeutics' Q3 Net Loss Widens

Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
AKRO

GlobeNewswire

2 months ago

Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

AKRO

MT Newswires

2 months ago

Akero Therapeutics Insider Sold Shares Worth $3,438,312, According to a Recent SEC Filing

Madrigal, 89Bio jump after Novo’s semaglutide shows promise in MASH
AKRO

TipRanks

3 months ago

Madrigal, 89Bio jump after Novo’s semaglutide shows promise in MASH

Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024
AKRO

GlobeNewswire

3 months ago

Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024

State Street Corp's Strategic Reduction in Akero Therapeutics Inc Shares
AKRO

GuruFocus.com

3 months ago

State Street Corp's Strategic Reduction in Akero Therapeutics Inc Shares

Akero Therapeutics (AKRO): Leading the Charge in MASH Treatment with Efruxifermin
AKRO

Insider Monkey

3 months ago

Akero Therapeutics (AKRO): Leading the Charge in MASH Treatment with Efruxifermin

Akero Therapeutics, Inc. (AKRO): A Visionary Small-Cap Stock Pick by Hedge Funds
AKRO

Insider Monkey

3 months ago

Akero Therapeutics, Inc. (AKRO): A Visionary Small-Cap Stock Pick by Hedge Funds

Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference
AKRO

GlobeNewswire

4 months ago

Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference

Wellington Management Group LLP's Strategic Acquisition in Akero Therapeutics Inc
AKRO

GuruFocus.com

4 months ago

Wellington Management Group LLP's Strategic Acquisition in Akero Therapeutics Inc

Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH
AKRO

GlobeNewswire

4 months ago

Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH

Akero Therapeutics, Inc. (AKRO): This Small-Cap Healthcare Stock Is A Good Buy Right Now
AKRO

Insider Monkey

4 months ago

Akero Therapeutics, Inc. (AKRO): This Small-Cap Healthcare Stock Is A Good Buy Right Now

Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
AKRO

GlobeNewswire

5 months ago

Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

AKRO

MT Newswires

5 months ago

Akero Therapeutics Insider Sold Shares Worth $386,714, According to a Recent SEC Filing

AKRO

MT Newswires

5 months ago

Akero Therapeutics Shares Fall After Q2 Loss Widens

Amicus (FOLD) Up as Q2 Earnings & Sales Top, '24 View Updated
AKRO

Zacks

5 months ago

Amicus (FOLD) Up as Q2 Earnings & Sales Top, '24 View Updated

Xenon (XENE) Q2 Earnings Miss, Pipeline in Focus, Stock Down
AKRO

Zacks

5 months ago

Xenon (XENE) Q2 Earnings Miss, Pipeline in Focus, Stock Down

Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
AKRO

GlobeNewswire

5 months ago

Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Zoetis (ZTS) Q2 Earnings & Revenues Beat, '24 Outlook Raised
AKRO

Zacks

5 months ago

Zoetis (ZTS) Q2 Earnings & Revenues Beat, '24 Outlook Raised

AKRO

MT Newswires

6 months ago

Akero Therapeutics Insider Sold Shares Worth $4,381,867, According to a Recent SEC Filing

Akero Therapeutics (AKRO) Moves to Buy: Rationale Behind the Upgrade
AKRO

Zacks

6 months ago

Akero Therapeutics (AKRO) Moves to Buy: Rationale Behind the Upgrade

AKRO

MT Newswires

7 months ago

Wolfe Research Initiates Coverage on Akero Therapeutics With Outperform Rating, $40 Price Target

Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH
AKRO

GlobeNewswire

7 months ago

Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024
AKRO

GlobeNewswire

7 months ago

Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024

Viking (VKTX) Falls 10% Despite Upbeat NASH Study Results
AKRO

Zacks

7 months ago

Viking (VKTX) Falls 10% Despite Upbeat NASH Study Results

Akero Therapeutics to Present at the Jefferies Global Healthcare Conference
AKRO

GlobeNewswire

8 months ago

Akero Therapeutics to Present at the Jefferies Global Healthcare Conference

AKRO

MT Newswires

8 months ago

Evercore ISI Adjusts Price Target on Akero Therapeutics to $38 From $50, Maintains Outperform Rating

Akero Therapeutics Inc (AKRO) Q1 2024 Earnings: Misses Analyst Forecast Amid Continued ...
AKRO

GuruFocus.com

8 months ago

Akero Therapeutics Inc (AKRO) Q1 2024 Earnings: Misses Analyst Forecast Amid Continued ...

AKRO

MT Newswires

8 months ago

Akero Therapeutics' Q1 Net Loss Widens; Cash Expected to Fund Operations Into H2 2027

Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
AKRO

GlobeNewswire

8 months ago

Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Akero Therapeutics to Present at the BofA Securities 2024 Health Care Conference
AKRO

GlobeNewswire

8 months ago

Akero Therapeutics to Present at the BofA Securities 2024 Health Care Conference

Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer
AKRO

GlobeNewswire

9 months ago

Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer

Billionaire Steve Cohen and Insiders Are Buying These 10 Stocks
AKRO

Insider Monkey

10 months ago

Billionaire Steve Cohen and Insiders Are Buying These 10 Stocks

Ozempic Can’t Do It All—A Potential New Blockbuster Is a Reminder of That
AKRO

The Wall Street Journal

10 months ago

Ozempic Can’t Do It All—A Potential New Blockbuster Is a Reminder of That

Madrigal (MDGL) Stock Up as FDA Approves First Drug for NASH
AKRO

Zacks

10 months ago

Madrigal (MDGL) Stock Up as FDA Approves First Drug for NASH

Ionis (IONS) Drug Meets Mid-Stage MASH Study Goals
AKRO

Zacks

10 months ago

Ionis (IONS) Drug Meets Mid-Stage MASH Study Goals

Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
AKRO

GlobeNewswire

10 months ago

Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology
AKRO

GlobeNewswire

10 months ago

Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology

President and CEO Andrew Cheng Sells 75,000 Shares of Akero Therapeutics Inc (AKRO)
AKRO

GuruFocus.com

10 months ago

President and CEO Andrew Cheng Sells 75,000 Shares of Akero Therapeutics Inc (AKRO)

Akero Therapeutics Announces Pricing of Public Offering of Common Stock
AKRO

GlobeNewswire

10 months ago

Akero Therapeutics Announces Pricing of Public Offering of Common Stock

Akero (AKRO) Up on Upbeat Week 96 Data From Liver Disease Study
AKRO

Zacks

10 months ago

Akero (AKRO) Up on Upbeat Week 96 Data From Liver Disease Study

Akero Therapeutics Announces Proposed Public Offering of Common Stock
AKRO

GlobeNewswire

10 months ago

Akero Therapeutics Announces Proposed Public Offering of Common Stock

Why Akero Rocketed — And Pulled Rival 89bio Higher — On Results In Liver Disease Treatment
AKRO

Investor's Business Daily

10 months ago

Why Akero Rocketed — And Pulled Rival 89bio Higher — On Results In Liver Disease Treatment

Data Suggests Makers of Fatty Liver Treatments Won’t Be Displaced by Obesity Drugs
AKRO

The Wall Street Journal

10 months ago

Data Suggests Makers of Fatty Liver Treatments Won’t Be Displaced by Obesity Drugs

Akero Therapeutics Bats Back Challenge From Lilly in Emerging Liver-Drug Market
AKRO

Barrons.com

10 months ago

Akero Therapeutics Bats Back Challenge From Lilly in Emerging Liver-Drug Market

Akero Rockets 27%, Prodding Rival 89bio Higher, On Promising Liver Disease Treatment
AKRO

Investor's Business Daily

a year ago

Akero Rockets 27%, Prodding Rival 89bio Higher, On Promising Liver Disease Treatment

AKRO

Reuters

a year ago

UPDATE 1-Akero's lead drug helps reduce scarring in fatty liver disease patients

AKRO

Reuters

a year ago

Akero's lead drug helps improve scarring in fatty liver disease patients

Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
AKRO

GlobeNewswire

a year ago

Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study

Akero strengthens MASH drug’s case with new study data
AKRO

BioPharma Dive

a year ago

Akero strengthens MASH drug’s case with new study data

Wall Street Analysts Predict a 58.87% Upside in Akero Therapeutics, Inc. (AKRO): Here's What You Should Know
AKRO

Zacks

a year ago

Wall Street Analysts Predict a 58.87% Upside in Akero Therapeutics, Inc. (AKRO): Here's What You Should Know

Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efruxifermin in Patients with Pre-Cirrhotic MASH
AKRO

GlobeNewswire

a year ago

Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efruxifermin in Patients with Pre-Cirrhotic MASH

Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
AKRO

GlobeNewswire

a year ago

Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Are Medical Stocks Lagging GSK PLC Sponsored ADR (GSK) This Year?
AKRO

Zacks

a year ago

Are Medical Stocks Lagging GSK PLC Sponsored ADR (GSK) This Year?

Here's Why Akero Therapeutics, Inc. (AKRO) Is a Great 'Buy the Bottom' Stock Now
AKRO

Zacks

a year ago

Here's Why Akero Therapeutics, Inc. (AKRO) Is a Great 'Buy the Bottom' Stock Now

Is Akero Therapeutics (AKRO) Stock Outpacing Its Medical Peers This Year?
AKRO

Zacks

a year ago

Is Akero Therapeutics (AKRO) Stock Outpacing Its Medical Peers This Year?

Why BankUnited, Inc. (BKU) is a Great Dividend Stock Right Now
AKRO

Zacks

a year ago

Why BankUnited, Inc. (BKU) is a Great Dividend Stock Right Now

High Bar Brands makes splash at HDAW
AKRO

GlobeNewswire

a year ago

High Bar Brands makes splash at HDAW

How to Find Strong Business Services Stocks Slated for Positive Earnings Surprises
AKRO

Zacks

a year ago

How to Find Strong Business Services Stocks Slated for Positive Earnings Surprises

Gabelli Funds to Host Pump, Valve & Water Systems Symposium at The Yale Club, New York, NY
AKRO

GlobeNewswire

a year ago

Gabelli Funds to Host Pump, Valve & Water Systems Symposium at The Yale Club, New York, NY

Virtu Financial, Inc. (NASDAQ:VIRT) Q4 2023 Earnings Call Transcript
AKRO

Insider Monkey

a year ago

Virtu Financial, Inc. (NASDAQ:VIRT) Q4 2023 Earnings Call Transcript

Why DigitalOcean Holdings, Inc. (DOCN) Dipped More Than Broader Market Today
AKRO

Zacks

a year ago

Why DigitalOcean Holdings, Inc. (DOCN) Dipped More Than Broader Market Today

AKRO

Thomson Reuters StreetEvents

a year ago

Q4 2023 WesBanco Inc Earnings Call

Hot Picks: 7 Stocks Wall Street Expects to Double in 2024
AKRO

InvestorPlace

a year ago

Hot Picks: 7 Stocks Wall Street Expects to Double in 2024

Wesbanco Inc (WSBC) Reports Mixed Results Amidst Economic Headwinds
AKRO

GuruFocus.com

a year ago

Wesbanco Inc (WSBC) Reports Mixed Results Amidst Economic Headwinds

NuStar Energy L.P. (NS) Stock Jumps 18.3%: Will It Continue to Soar?
AKRO

Zacks

a year ago

NuStar Energy L.P. (NS) Stock Jumps 18.3%: Will It Continue to Soar?

AKRO

Thomson Reuters StreetEvents

a year ago

Q4 2023 Enterprise Financial Services Corp Earnings Call

Terreno Realty Corporation Announces Redevelopment in Gardena, CA
AKRO

Business Wire

a year ago

Terreno Realty Corporation Announces Redevelopment in Gardena, CA

Enterprise Financial Services (EFSC) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
AKRO

Zacks

a year ago

Enterprise Financial Services (EFSC) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Are Investors Undervaluing Edgewell Personal Care (EPC) Right Now?
AKRO

Zacks

a year ago

Are Investors Undervaluing Edgewell Personal Care (EPC) Right Now?

Stock Market News for Jan 18, 2024
AKRO

Zacks

a year ago

Stock Market News for Jan 18, 2024

Progress Software Corporation (NASDAQ:PRGS) Q4 2023 Earnings Call Transcript
AKRO

Insider Monkey

a year ago

Progress Software Corporation (NASDAQ:PRGS) Q4 2023 Earnings Call Transcript

Is Now An Opportune Moment To Examine Liberty Latin America Ltd. (NASDAQ:LILA)?
AKRO

Simply Wall St.

a year ago

Is Now An Opportune Moment To Examine Liberty Latin America Ltd. (NASDAQ:LILA)?

Winners And Losers Of Q3: PagerDuty (NYSE:PD) Vs The Rest Of The Software Development Stocks
AKRO

StockStory

a year ago

Winners And Losers Of Q3: PagerDuty (NYSE:PD) Vs The Rest Of The Software Development Stocks

Bull of the Day: NeoGenomics (NEO)
AKRO

Zacks

a year ago

Bull of the Day: NeoGenomics (NEO)

Growth Stocks on the Brink: 7 Picks Poised for Explosive Returns
AKRO

InvestorPlace

a year ago

Growth Stocks on the Brink: 7 Picks Poised for Explosive Returns

Brokers Suggest Investing in Tecnoglass (TGLS): Read This Before Placing a Bet
AKRO

Zacks

a year ago

Brokers Suggest Investing in Tecnoglass (TGLS): Read This Before Placing a Bet

Mason Hawkins Adjusts Stake in Oscar Health Inc
AKRO

GuruFocus.com

a year ago

Mason Hawkins Adjusts Stake in Oscar Health Inc

Q3 Earnings Highlights: Braze (NASDAQ:BRZE) Vs The Rest Of The Sales And Marketing Software Stocks
AKRO

StockStory

a year ago

Q3 Earnings Highlights: Braze (NASDAQ:BRZE) Vs The Rest Of The Sales And Marketing Software Stocks

The 3 Best Under-$10 Stocks to Buy in January 2024
AKRO

InvestorPlace

a year ago

The 3 Best Under-$10 Stocks to Buy in January 2024

The past three years for Kennametal (NYSE:KMT) investors has not been profitable
AKRO

Simply Wall St.

a year ago

The past three years for Kennametal (NYSE:KMT) investors has not been profitable

There's Been No Shortage Of Growth Recently For GMS' (NYSE:GMS) Returns On Capital
AKRO

Simply Wall St.

a year ago

There's Been No Shortage Of Growth Recently For GMS' (NYSE:GMS) Returns On Capital

Director Laurence Charney Sells 17,500 Shares of TG Therapeutics Inc
AKRO

GuruFocus.com

a year ago

Director Laurence Charney Sells 17,500 Shares of TG Therapeutics Inc

U.S. Physical Therapy to Present at the 42nd Annual J.P. Morgan Healthcare Conference
AKRO

Business Wire

a year ago

U.S. Physical Therapy to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Gentherm Unveils WellSense™ “A Symphony of Sensations” during CES 2024
AKRO

GlobeNewswire

a year ago

Gentherm Unveils WellSense™ “A Symphony of Sensations” during CES 2024

Will Affiliated Managers (AMG) Beat Estimates Again in Its Next Earnings Report?
AKRO

Zacks

a year ago

Will Affiliated Managers (AMG) Beat Estimates Again in Its Next Earnings Report?

Do Fundamentals Have Any Role To Play In Driving U.S. Physical Therapy, Inc.'s (NYSE:USPH) Stock Up Recently?
AKRO

Simply Wall St.

a year ago

Do Fundamentals Have Any Role To Play In Driving U.S. Physical Therapy, Inc.'s (NYSE:USPH) Stock Up Recently?

Where Will ZIM Stock Be in 2024?
AKRO

Motley Fool

a year ago

Where Will ZIM Stock Be in 2024?

Cal-Maine Foods (CALM) Just Overtook the 20-Day Moving Average
AKRO

Zacks

a year ago

Cal-Maine Foods (CALM) Just Overtook the 20-Day Moving Average

Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further expand its decentralized CAR-T manufacturing network in the U.S.
AKRO

GlobeNewswire

a year ago

Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further expand its decentralized CAR-T manufacturing network in the U.S.

Collegium (COLL) Shares Rise on Financial Outlook for 2024
AKRO

Zacks

a year ago

Collegium (COLL) Shares Rise on Financial Outlook for 2024

Share on Social Networks: